Three clinical isolates of Staphylococcus aureus, which were previously shown to contain a 50S plasmid conferring resistance to several aminoglycosides, were examined for modifying enzymes. Both the wild-type and heat-cured derivatives of the isolates were screened for acetyl-, adenylyl-, and phosphotransferase activities. The substrates were ntamicin, amikacin and ilniieir the results indicated that even though all three activites were present, the phosphotransferase reaction was most respo i otice-es_eantibiotics. The absence of any of the modifying activites in cured derivatives of the three isolates supports the conclusion that aminoglycoside resistance in these strains is conferred by a plasmid.
Gentamicin resistance in clinical isolates of Staphylococcus aureus has been reported in Europe (4, 7, 9, 10) and the United States (11) . Recent studies in this laboratory identified a 50S plasmid in two strains as the genetic element responsible for this resistance (11) . The organisms studied were recovered from an outbreak of infections in our neonatal intensive care unit (Talmadge Memorial Hospital, Augusta, Ga.) and were of different phage types. Speller et al. (10) reported an outbreak in three hospitals by a single strain of gentamicin-resistant S. aureus. In France, Le Goffic et al. (7) have studied a gentamicin-resistant strain isolated from a blood culture.
Since gentamicin resistance in S. aureus has only recently been noted in clinical isolates, we undertook the biochemical characterization of our strains in an effort to determine which of several possible modifying enzymes could be involved in this resistance. We now describe the relative susceptibility of gentamicin, amikacin, and netilmicin to acetyltransferase (AAC) adenylyltransferase (ANT), and phosphotransferase (APT) modification by crude cell-free extracts of our S. aureus strains.
MATERIALS AND METHODS The strains studied by Le Goffic and co-workers (6, 7) are also apparently different from our strains. Their ApOl strain produced an ANT(4') that modified several aminoglycosides but not the gentamicin components (6) . More recently, these workers (7) reported S. aureus R. Palm to possess an AAC(6') and an APT(2"), but apparently this strain did not produce an ANT with activity for the gentamicins.
The Cambridge strains studied by Dowding 300 oo (4) also possess AAC(6') and two APT activities -0 apparently acting on the 3' and the 2" hydroxyl ndence ofthe APT en-groups of aminoglycosides. ract of S. aureus GorBecause of differences in methods and approaches to the study of the organisms, comparisons of strains are very difficult. However, our interested in char-finding that the apparent Km for amikacin is two led in a recent out-orders of ma nituce higher than that for the Pn.lvp rarp imit. f-n. establish how similar our strains are to those in Europe and elsewhere in the United States. Based on published studies to date, our strains are apparently different from other gentamicinresistant S. aureus isolates.
Speller et al. (10) reported that extracts of their gentamicin-resistant strain, which is amikacin susceptible, possessed both ANT and AAC activities toward gentamicin but not toward amikacin. Those workers apparently did not test for APT activity.
Brown et al.
(1) tested strain 5532, which was isolated by Porthouse et al. (9) , and found APT activity with gentamicin, but not with amikacin. Both gentamicin and amikacin were acetylated, but no adenylylation of the aminoglycosides was reported.
Phillips et al. (8) examined several gentamicin-resistant strains and found that most pron=rgr~compiex suggess mat-previous re-'ports indicatmgana~bsence of APT activity with amikacin may have resulted from the use of too low a concentration of amikacin in the assays (1, 8) . It should be noted that Courvalin and Davies (2) report that amikacin is also a poor substrate for the S. aureus APT(3') enzyme. As judged by the observed substrate specificities, our strains possess both the AAC(6') and the APT(2") activities reported for the European strains (4, 7) . In addition an ANT activity is elaborated in our strains. Although this finding confirms the report of Speller et al. (10) that gentamicin may be adenylylated, our ANT differsfro thirsin that it also ade~nylvLated~ann~-kacin. The site of adenylylation remains to be dtrmed.
Bacterial resistance to aminoglycosides is generally considered to require the enzymic modification of the antibiotic in the outer layers of 644 SCOTT ET AL. the cell, and this modification results in an inhibition of the uptake of the antibiotic rather than in its inactivation (3) . In theory, gentamicin resistance in S. aureus could be explained by the possession of any one of the three modification enzymes. However, a comparison of the MICs and the degrees of enzymatic modification found for the aminoglycosides used in the present report and in that of LeGoffic et al. (7) reveals that the MJs of the aminoglycosides are most niQPy related to their susceptibilities to modification by APT(2"). In addition,.all gentamicinaeiss of S. aureus examne date inve y,T wet i dhthat netilmicin is not adenylylated, and only poorly acetylated, but it is appreciably phosphorylated. Since our strains are also resistant to this aminoglycoside, we conclude that the APT(2") enzyme is most responsible for conferring resistance to these three aminoglycosides in our S. aureus strains.
